Compare Organon & Co. Common Stock (OGN) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs S&P Global Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while S&P Global Inc trades at $411 (market cap $120.87B). The key difference: S&P Global Inc is far larger — about 33.4× Organon & Co. Common Stock's market cap, and S&P Global Inc pays the higher dividend (0.95%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and S&P Global Inc for 124 Days on average.
| OGN | SPGI | |
|---|---|---|
Market Cap | $3.62B | $120.87B |
Volume | 2,892,999 | 1,391,754 |
Sector | Health | Financials |
52-Week High | $13.81 | $517.92 |
52-Week Low | $5.70 | $370.42 |
Typical Hold Time | 0 Days | 124 Days |
Enterprise Value | $11.04B | $132.35B |
Dividend Yield | 0.58% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
S&P Global (SPGI) trades at $408.57, down 0.88% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong fundamentals with Q1 and Q2 2026 earnings beats, revenue growth to $15.34B in 2025, and robust profitability margins. Recent news highlights expansion into digital asset risk assessment and AI-driven growth initiatives.
Outlook remains positive with an 85.7% analyst buy rating and a $509.50 consensus price target, implying significant upside. Key risks include execution of acquisitions and macroeconomic sensitivity, but the firm's entrenched market position and cash flow stability support a favorable investment case for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
